171 related articles for article (PubMed ID: 22051162)
21. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
[TBL] [Abstract][Full Text] [Related]
22. Additive effects of miglitol and anagliptin on insulin-treated type 2 diabetes mellitus: a case study.
Kishimoto M; Noda M
Clin Drug Investig; 2015 Feb; 35(2):141-7. PubMed ID: 25511640
[TBL] [Abstract][Full Text] [Related]
23. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
24. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
25. A case of insulinoma following total gastrectomy--effects of an alpha-glucosidase inhibitor on suppressing GIP and GLP-1 elevations.
Sato T; Narita T; Hosoba M; Kakei M; Nanjo H; Uchinami H; Satoh K; Yamamoto Y; Yamada Y
Diabetes Res Clin Pract; 2010 Apr; 88(1):e4-6. PubMed ID: 20122751
[TBL] [Abstract][Full Text] [Related]
26. Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring.
Matsuura K; Mori Y; Nakamura A; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2012 May; 14(5):423-9. PubMed ID: 22316114
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
[TBL] [Abstract][Full Text] [Related]
28. Gut carbohydrate inhibits GIP secretion via a microbiota/SCFA/FFAR3 pathway.
Lee EY; Zhang X; Miyamoto J; Kimura I; Taknaka T; Furusawa K; Jomori T; Fujimoto K; Uematsu S; Miki T
J Endocrinol; 2018 Dec; 239(3):267-276. PubMed ID: 30400014
[TBL] [Abstract][Full Text] [Related]
29. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550
[TBL] [Abstract][Full Text] [Related]
30. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
31. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Jones RB; Vickers SP; Cheetham SC; Headland KR; Mark M; Klein T
Eur J Pharmacol; 2014 Apr; 729():59-66. PubMed ID: 24530555
[TBL] [Abstract][Full Text] [Related]
32. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
[TBL] [Abstract][Full Text] [Related]
33. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
[TBL] [Abstract][Full Text] [Related]
34. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol.
Uzu T; Yokoyama H; Itoh H; Koya D; Nakagawa A; Nishizawa M; Maegawa H; Yokomaku Y; Araki S; Abiko A; Haneda M
Clin Exp Nephrol; 2011 Feb; 15(1):58-63. PubMed ID: 20824296
[TBL] [Abstract][Full Text] [Related]
36. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
Aoki K; Kato H; Terauchi Y
Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
[TBL] [Abstract][Full Text] [Related]
37. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
38. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT.
Alssema M; Rijkelijkhuizen JM; Holst JJ; Teerlink T; Scheffer PG; Eekhoff EM; Gastaldelli A; Mari A; Hart LM; Nijpels G; Dekker JM
Eur J Endocrinol; 2013 Oct; 169(4):421-30. PubMed ID: 23864340
[TBL] [Abstract][Full Text] [Related]
39. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Dash RP; Babu RJ; Srinivas NR
Xenobiotica; 2018 Jan; 48(1):89-108. PubMed ID: 28010166
[TBL] [Abstract][Full Text] [Related]
40. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
